CYP19A1 and breast cancer: The hormonally active vitamin D3 metabolite 1,25(OH)2D3 (calcitriol) is known to exhibit therapeutic effects against breast cancer, mainly by lowering the expression of estrogen receptors and aromatase activity [19,20].